Cassava Sciences Inc. (SAVA:NSD) Analysts rate as a Hold, 4 Bearish Signal’s Detected

STA Research
by: STA Research
Cassava Sciences Inc.

Based on the Cassava Sciences Inc. stock forecasts from 2 analysts, the average analyst Sava stock price is USD 36.67 over the next 12 months. Cassava Sciences Inc.’s average analyst rating is Hold. Stock Target Advisor’s own stock analysis of Cassava Sciences Inc. is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Cassava Sciences Inc.’s stock price was USD 20.21. Cassava Sciences Inc.’s stock price has changed by +0.00% over the past week, -3.70% over the past month and -80.68% over the last year.

Cassava Sciences, Inc. is a biotechnology business that is in the clinical stage of its development and is working on medications to treat neurological illnesses. Its primary investigated diagnostic product candidate, SavaDx, is a blood-based biomarker and diagnostic test for Alzheimer’s disease. Its primary investigational therapeutic product candidate, simufilam, is a small molecule medication that has successfully completed Phase 2b clinical testing. Cassava Sciences, Inc. replaced Pain Therapeutics, Inc. as the official name of the business in March 2019, after it had previously been known by the former moniker. Cassava Sciences, Inc. was established in 1998 and currently operates out of its headquarters in Austin, Texas.

 

What we like about Sava Stock Price:

(Bullish Signals)

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk-adjusted returns

Sava stock forecast: This stock has performed well, on a risk-adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

 

What we don’t like about Sava Stock Price:

(Bearish Signals)

High volatility

The total returns for this company are volatile and above the median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peer’s median on a price-to-book value basis.

Negative cash flow

Sava stock price downgrade reason: The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

Sava stock price downgrade reason: The company had negative total free cash flow in the most recent four quarters.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.